Buchumschlag

People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Xuan Li, Dachuang Cao, Helene Sapin, Fangyu Wang, Theresa Hunter Gibble, Nedina Kalezic Raibulet, Max Denning, Lee M. Kaplan
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Obesity
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4
von: Theresa Hunter Gibble, et al.
Veröffentlicht: (2025)

Tirzepatide and health‐related quality of life in adults with obesity or overweight: Results from the SURMOUNT ‐3 phase 3 randomized trial
von: Theresa Hunter Gibble, et al.
Veröffentlicht: (2025)

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
von: Andreea Ciudin, et al.
Veröffentlicht: (2026)

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT
von: Thomas A. Wadden, et al.
Veröffentlicht: (2026)

Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials
von: Evgenia Gourgari, et al.
Veröffentlicht: (2025)

Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
von: Michelle Look, et al.
Veröffentlicht: (2025)

Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide
von: Man Sun, et al.
Veröffentlicht: (2026)

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT ‐1 Over 176 Weeks
von: Hiddo J. L. Heerspink, et al.
Veröffentlicht: (2026)

Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database
von: Emily R. Hankosky, et al.
Veröffentlicht: (2025)

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
von: Alpana P. Shukla, et al.
Veröffentlicht: (2025)

Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide
von: Rodolfo J. Galindo, et al.
Veröffentlicht: (2025)

Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’
von: Chih‐Yuan Wang
Veröffentlicht: (2026)

Real‐world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database
von: Theresa Hunter Gibble, et al.
Veröffentlicht: (2025)

Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice
von: Hamlet Gasoyan, et al.
Veröffentlicht: (2025)

Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review
von: Geeta Pardeshi, et al.
Veröffentlicht: (2025)

Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults
von: Mai Katsura, et al.
Veröffentlicht: (2026)

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
von: Emily R. Hankosky, et al.
Veröffentlicht: (2025)

Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide
von: Sarah R. Barenbaum, et al.
Veröffentlicht: (2026)

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN
von: Deborah B. Horn, et al.
Veröffentlicht: (2025)

Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights
von: Emiliano G. Manueli Laos, et al.
Veröffentlicht: (2026)

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial
von: Yasushi Ishigaki, et al.
Veröffentlicht: (2026)

Tirzepatide in the NHS : The known unknowns of treating obesity at a national scale
von: Ashley Kieran Clift, et al.
Veröffentlicht: (2025)

Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta‐Analysis
von: Jian‐Ying Wang, et al.
Veröffentlicht: (2025)

Interpreting Lean Mass Changes During Tirzepatide‐Induced Weight Loss: Beyond Quantitative Metrics
von: Tuba Uyanık
Veröffentlicht: (2026)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
von: Iskandar Idris
Veröffentlicht: (2024)

Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis
von: A. B. M. Kamrul‐Hasan, et al.
Veröffentlicht: (2024)

A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide
von: Anna K. Jansson, et al.
Veröffentlicht: (2026)

Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
von: Sharath Kommu, et al.
Veröffentlicht: (2025)

Time to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials
von: Deborah B. Horn, et al.
Veröffentlicht: (2025)

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
von: Domenica M. Rubino, et al.
Veröffentlicht: (2025)

Real‐World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido‐ TZP Study
von: Fumika Maruyama, et al.
Veröffentlicht: (2026)

Six‐Month Real‐World Effectiveness, Persistence and Safety of Low‐to‐Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study
von: Nikolaos Angelopoulos, et al.
Veröffentlicht: (2026)

Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT ‐J Study
von: Hiroaki Masuzaki, et al.
Veröffentlicht: (2026)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
von: Iskandar Idris
Veröffentlicht: (2024)

Retatrutide Shows Multiple Metabolic Benefits in Diet‐Induced Obese MASH Mouse and Hamster Models
von: François Briand, et al.
Veröffentlicht: (2026)

Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial
von: Lin Zhao, et al.
Veröffentlicht: (2025)

The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China
von: Sihua Wang, et al.
Veröffentlicht: (2025)

The role of gut–islet axis in pancreatic islet function and glucose homeostasis
von: Qi Chen, et al.
Veröffentlicht: (2025)

Mindful eating and its relationship with body mass index, binge eating, anxiety and negative affect
von: Sheila Pintado-Cucarella
Veröffentlicht: (2016)

One Year of Exercise After Weight Loss Increases Postprandial GLP ‐1 Secretion in Contrast to Usual Activity or GLP ‐1 Receptor Agonist Treatment
von: Joachim Holt, et al.
Veröffentlicht: (2025)